Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Benitec Biopharma, Inc. (BNTC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.64-6.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BNTC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain disciplined cash management and control operating expenses | Management focuses on cash discipline despite net losses rising to -$11.9M in 2026-Q3. | Broken | cash burn worsens beyond -$5M per quarter | Cash from operations: $-4.939M FY2026-Q4; GAAP. Published target: Quarterly cash from operations better than -$4.5M. Target period is not explicitly aligned with this observation. Sep 14, 2026-4,939,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not a profitable operating business: BNTC reported no revenue and a substantial net loss in fiscal 2026. The multi-year thesis is in a watch state, with clinical work advancing but the timing and design of the pivotal study still uncertain.
The evidence does not provide a valuation comparison or clear measure of market expectations, so whether BNTC is cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that does not establish that the market has priced in the clinical and financial risks.
Near term, the business is likely to remain loss-making as it develops BB-301; fiscal 2026 net loss was $45.5 million, with no revenue. Clinical progress includes Cohort 2 enrollment, but the FDA has requested additional data before confirming the pivotal design, and the mid-2027 trial timing depends on that work. Cash was $180.0 million at June 30, 2026, while total fiscal-year expenses rose from the prior year; a next-call guidance cut is a stated risk.
The multi-year thesis hinges on whether FDA discussions resolve the additional-data request and allow the pivotal study to proceed on the stated timeline. Near term, guidance and the next financial report are key risks; weaker jobs data could also weigh on healthcare names, while continued strong results from sector bellwethers could support sector momentum.
For the next 1 to 3 years, BNTC remains a high-risk clinical-development story with meaningful cash but no revenue, and the pivotal-study path is not yet confirmed. The evidence supports close attention to regulatory progress, spending, and guidance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “As of June 30, 2026, the Company had $180.0 million in cash and cash equivalents.” “As of March 31, 2026, the Company had $184.8 million in cash and cash equivalents, which includes $0.5 million from the exercise of warrants during the nine-month period ended March 31, 2026.”
Advance clinical development of gene-silencing therapies | Benitec advances gene-silencing therapies with a 66% progress score. | Intact | progress score falls below 50% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Strengthen leadership and governance | A supporting condition in Benitec Biopharma, Inc.'s published investment case. The stated target is Maintain stable executive team and governance. | Intact | Major leadership disruption or governance failure | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Improve net income trend | A supporting condition in Benitec Biopharma, Inc.'s published investment case. The stated target is Net income loss less than -$11.9M per quarter. | Intact | net income loss exceeds -$15M per quarter | Net income: $-12.809M FY2026-Q4; GAAP. Published target: Net income loss less than -$11.9M per quarter. Target period is not explicitly aligned with this observation. Sep 14, 2026-12,809,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “As of June 30, 2026, the Company had $180.0 million in cash and cash equivalents.” “As of March 31, 2026, the Company had $184.8 million in cash and cash equivalents, which includes $0.5 million from the exercise of warrants during the nine-month period ended March 31, 2026.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.48 → $-1.49 · observed estimates
$0.07B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.48 | $71,100,000 | 1 / 2 |
| 2026-07-25 | $-1.48 | $71,100,000 | 1 / 2 |
| 2026-07-26 | $-1.48 | $71,100,000 | 1 / 2 |
| 2026-07-27 | $-1.48 | $71,100,000 | 1 / 2 |
| 2026-07-28 | $-1.48 | $71,100,000 | 1 / 2 |
| 2026-07-29 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-07-30 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-07-31 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-01 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-02 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-03 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-04 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-05 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-06 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-07 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-08 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-09 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-10 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-11 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-12 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-13 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-14 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-15 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-16 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-17 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-18 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-19 | $-1.39 | $71,100,000 | 2 / 3 |
| 2026-08-20 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-21 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-22 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-23 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-24 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-25 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-26 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-27 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-28 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-29 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-30 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-08-31 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-01 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-02 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-03 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-04 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-05 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-06 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-07 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-08 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-09 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-10 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-11 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-12 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-13 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-14 | $-1.19 | $71,100,000 | 2 / 3 |
| 2026-09-15 | $-1.34 | $71,100,000 | 1 / 3 |
| 2026-09-16 | $-1.42 | $71,100,000 | 1 / 3 |
| 2026-09-17 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-18 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-19 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-20 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-21 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-22 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-23 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-24 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-25 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-26 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-27 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-28 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-29 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-09-30 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-01 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-02 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-03 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-04 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-05 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-06 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-07 | $-1.43 | $71,100,000 | 1 / 3 |
| 2026-10-08 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-09 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-10 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-11 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-12 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-13 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-14 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-15 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-16 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-17 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-18 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-19 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-20 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-21 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-22 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-23 | $-1.43 | $23,700,000 | 1 / 3 |
| 2026-10-24 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-25 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-26 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-27 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-28 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-29 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-30 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-10-31 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-11-01 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-11-02 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-11-03 | $-1.49 | $17,775,000 | 2 / 4 |
| 2026-11-04 | $-1.49 | $17,775,000 | 2 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.